Abstract
Background: Pharmacoresistant epilepsy is a disabling neuronal disorder with harmful consequences that impact patient’s quality of life. Although psychiatric comorbidities are frequently present in patients with epilepsy, they are more common in those patients with pharmacoresistant epilepsy. Despite medical advances, the current existing therapeutic strategies for pharmacoresistant seizure control are not available for all patients and/or present disadvantages. Moreover, the conventional drug therapies for psychiatric comorbidities have several adverse effects. Therefore, in this field, nanotechnology arises as a novel tool for transporting drugs to the brain under pathological conditions with high efficiency and low side effects.
Objective: Present an overview of nanotechnology as a novel, efficient and enhanced therapeutic strategy for controlling pharmacoresistant epilepsy and its associated psychiatric comorbidities.
Conclusion: Nanotechnology emerges as a powerful tool for the control and/or treatment of pharmacoresistant epilepsy and its comorbidities in a more efficient and safer way than conventional treatments.
Keywords: Nanotechnology, Pharmacorresistant epilepsy, Psychiatric comorbidity, Seizures, Side effects.
Mini-Reviews in Medicinal Chemistry
Title:Nanotechnology as Potential Strategy for the Treatment of Pharmacoresistant Epilepsy and Comorbid Psychiatric Disorders
Volume: 17 Issue: 3
Author(s): Argelia Rosillo-de la Torre, Luisa Rocha, Hermelinda Salgado-Ceballos, Perla E. García Casillas and Gabriel Luna-Barcenas
Affiliation:
Keywords: Nanotechnology, Pharmacorresistant epilepsy, Psychiatric comorbidity, Seizures, Side effects.
Abstract: Background: Pharmacoresistant epilepsy is a disabling neuronal disorder with harmful consequences that impact patient’s quality of life. Although psychiatric comorbidities are frequently present in patients with epilepsy, they are more common in those patients with pharmacoresistant epilepsy. Despite medical advances, the current existing therapeutic strategies for pharmacoresistant seizure control are not available for all patients and/or present disadvantages. Moreover, the conventional drug therapies for psychiatric comorbidities have several adverse effects. Therefore, in this field, nanotechnology arises as a novel tool for transporting drugs to the brain under pathological conditions with high efficiency and low side effects.
Objective: Present an overview of nanotechnology as a novel, efficient and enhanced therapeutic strategy for controlling pharmacoresistant epilepsy and its associated psychiatric comorbidities.
Conclusion: Nanotechnology emerges as a powerful tool for the control and/or treatment of pharmacoresistant epilepsy and its comorbidities in a more efficient and safer way than conventional treatments.
Export Options
About this article
Cite this article as:
la Torre Rosillo-de Argelia, Rocha Luisa, Salgado-Ceballos Hermelinda, García Casillas E. Perla and Luna-Barcenas Gabriel, Nanotechnology as Potential Strategy for the Treatment of Pharmacoresistant Epilepsy and Comorbid Psychiatric Disorders, Mini-Reviews in Medicinal Chemistry 2017; 17 (3) . https://dx.doi.org/10.2174/1389557516666161013105000
DOI https://dx.doi.org/10.2174/1389557516666161013105000 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Safety and Efficacy of Levetiracetam for the Management of Levodopa- Induced Dyskinesia in Patients with Parkinson’s Disease: A Systematic Review
CNS & Neurological Disorders - Drug Targets Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration
Current Drug Metabolism Natural Polymeric Nanoparticles for Brain-Targeting: Implications on Drug and Gene Delivery
Current Pharmaceutical Design Susceptibility Genes for the Side Effect of Antipsychotics on Body Weight and Obesity
Current Drug Targets Metabotropic Glutamate Receptor 7: From Synaptic Function to Therapeutic Implications
Current Neuropharmacology Nicotinic Acetylcholine Receptors and Epilepsy
Current Drug Targets - CNS & Neurological Disorders Recent Developments in Group I Metabotropic Glutamate Receptor Allosteric Modulators for the Treatment of Psychiatric and Neurological Disorders (2014-May 2015)
Current Topics in Medicinal Chemistry An Overview on Chemistry and Biological Importance of Pyrrolidinone
Current Organic Synthesis Knowledge of Pharmacists about Anti-epileptic Drugs in a Developing Country
Current Drug Safety Synthesis and Anticonvulsant Activity of N-(trans)- 3-phenylprop-2-en-1-yl (Cinnamyl) Derivatives of Aminoalkanols
Letters in Drug Design & Discovery PDZ Domains at Excitatory Synapses: Potential Molecular Targets for Persistent Pain Treatment
Current Neuropharmacology Voltage-Dependent Na+ Channels as Targets of BACE1 - Implications for Neuronal Firing and Beyond
Current Alzheimer Research Epilepsy, Theories and Treatment Inside Corpus Hippocraticum
Current Pharmaceutical Design Non-Selective Cation Channel Blockers: Potential Use in Nervous System Basic Research and Therapeutics
Mini-Reviews in Medicinal Chemistry Oxidative/Nitrosative Brain Damage in Stress: Possible Target for Neuropsychopharmacological Drugs
Current Medicinal Chemistry - Central Nervous System Agents Melatonin and Respiratory Diseases: A Review
Current Topics in Medicinal Chemistry Measuring Receptor Occupancy with PET
Current Pharmaceutical Design Synaptic Plasticity as a Therapeutic Target in the Treatment of Autism-related Single-gene Disorders
Current Pharmaceutical Design Macronutrient Intake and Distribution in the Etiology, Prevention and Treatment of Osteosarcopenic Obesity
Current Aging Science To Analyze the Amelioration of Phenobarbital Induced Oxidative Stress by Erucin, as Indicated by Biochemical and Histological Alterations
Anti-Cancer Agents in Medicinal Chemistry